India and the United States are working together to fight the deadly coronavirus, and collaboration is underway in the areas of diagnosis and therapy of the disease, which to date has claimed the lives of more than 20,000 people in the world, according to the Indian envoy here.
The deadly coronavirus that first appeared in the city of Wuhan in China has spread dramatically around the world, infecting 471,518 people and causing 21,293 deaths, according to coronavirus tracker Johns Hopkins.
“In the current context of the COVID-19 pandemic, close collaboration in the fields of diagnosis and therapy of the disease is underway,” said Indian Ambassador to the United States, Taranjit Singh Sandhu , at PTI.
READ ALSO: Wall Street bonuses plummet 30%, layoffs likely as Covid-19 hits the market
“India and the United States have a long-standing productive partnership in the health care sector, particularly between research institutes and industries in the two countries,” he said.
As part of existing bilateral collaboration in the healthcare sector, the United States National Institute of Allergy and Infectious Diseases has shared important reagents with the Translational Health Science Technology Institute in Gurgaon.
Such cooperation should play a large role in the development of new therapies and reagent tests for COVID-19.
In addition, suppliers from American companies based in India are in contact with the Indian Medical Research Council to initiate and enhance the capabilities of the COVID-19 test in India.
“The United States will work side by side with India to fight the COVID epidemic. 19 Together we can protect our citizens and people around the world,” said Alice G Wells, Deputy Secretary of State acting for South Asia and Central Asia, in a tweet referring to cooperation between the two countries.
The United States, she said, is united with India and echoes Prime Minister Narendra Modi’s call to maintain their fighting spirit.
Cooperation and collaboration in the coronavirus sector were also discussed between the two countries when President Donald Trump met with Prime Minister Modi in New Delhi last month.
Trump and Modi also welcomed a bilateral memorandum of understanding that aims to promote access to high-quality, safe, effective, and affordable medicines for American and Indian consumers.
READ ALSO: LIVE Coronavirus: A Delhi doctor is positive; 800 visitors in quarantine
In 2012, the Center for Disease Control collaborated with the National Center for Disease Control to establish the Epidemic Intelligence Service (EIS) program.
This postgraduate field training program, modeled on the CDC’s Epidemiological Intelligence Service (EIS), has expanded to two additional centers at the WHO country office in India and the Indian Medical Research Council (ICMR) and the National Institute of Epidemiology.
According to the CDC, it has helped strengthen national surveillance to detect and respond to healthcare-associated infections and emerging threats of antimicrobial resistance in healthcare facilities in 22 states.
A public-private partnership has helped increase the capacity to diagnose, treat and treat patients with multidrug-resistant tuberculosis (MDR-TB) via virtual platforms. In Mumbai, the CDC helped the municipality and local partners to launch an airborne infection control unit to reduce the transmission of MDR-TB associated with healthcare.
The CDC helped India set up a surveillance system in 35 hospitals and 22 states for healthcare-associated infections. It assessed 346 laboratories across the country to identify needs and trained more than 1,700 laboratory workers on quality diagnostic testing / reporting of priority diseases.